Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.133
Buy
RSI(14)
70.985
Buy
STOCH(KDJ)(9,3,3)
84.821
Overbought
ATR(14)
0.362
High Vlolatility
CCI(14)
64.288
Neutral
Williams %R
15.549
Overbought
TRIX(12,20)
1.566
Sell
StochRSI(14)
0.000
Sell
Search
Evolus Inc
EOLSAdd to Watchlist
6.500USD
-0.080-1.22%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
428.06MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Evolus Inc
Currency: USD Updated: 2026-05-15Key Insights
Evolus Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 15 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.67.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Evolus Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Evolus Inc Highlights
StrengthsRisks
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 47.05% year-on-year.
Fairly Valued
The company’s latest PE is -9.73, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 50.03M shares, decreasing 24.26% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 7.50K shares of this stock.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
14.667
Target Price
+122.90%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Evolus Inc is 8.53, ranking 55 out of 155 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 73.14M, representing a year-over-year increase of 6.74%, while its net profit experienced a year-over-year increase of 43.50%.
Score
Financials
5.79
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
10.00
Operational Efficiency
10.00
Growth Potential
9.33
Shareholder Returns
7.52
Evolus Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Evolus Inc is 8.03, ranking 31 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -9.73, which is -53.30% below the recent high of -4.54 and -98.56% above the recent low of -19.32.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 15/155
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Evolus Inc is 8.57, ranking 26 out of 155 in the Pharmaceuticals industry. The average price target is 19.50, with a high of 20.00 and a low of 14.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
14.667
Target Price
+122.90%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Evolus Inc
EOLS
7
Amgen Inc
AMGN
38
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
33
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Evolus Inc is 9.43, ranking 15 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 7.29 and the support level at 5.17, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
6.524
Sell
MA10
6.364
Buy
MA20
5.792
Buy
MA50
5.062
Buy
MA100
5.109
Buy
MA200
5.996
Buy
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Evolus Inc is 7.00, ranking 51 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 75.98%, representing a quarter-over-quarter decrease of 14.84%. The largest institutional shareholder is James Simons, holding a total of 339.02K shares, representing 0.51% of shares outstanding, with 306.64% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Evolus Inc is 5.30, ranking 69 out of 155 in the Pharmaceuticals industry. The company's beta value is 1.33. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.33
VaR
+5.14%
240-Day Maximum Drawdown
+61.52%
240-Day Volatility
+71.65%
Return
Best Daily Return
60 days
+35.35%
120 days
+35.35%
5 years
+35.35%
Worst Daily Return
60 days
-8.91%
120 days
-12.24%
5 years
-28.51%
Sharpe Ratio
60 days
+2.22
120 days
+0.23
5 years
+0.12
Risk Assessment
Maximum Drawdown
240 days
+61.52%
3 years
+77.47%
5 years
+77.47%
Return-to-Drawdown Ratio
240 days
-0.57
3 years
-0.04
5 years
-0.11
Skewness
240 days
+1.11
3 years
+1.72
5 years
+1.24
Volatility
Realised Volatility
240 days
+71.65%
5 years
+64.26%
Standardised True Range
240 days
+5.37%
5 years
+7.87%
Downside Risk-Adjusted Return
120 days
+46.95%
240 days
+46.95%
Maximum Daily Upside Volatility
60 days
+109.10%
Maximum Daily Downside Volatility
60 days
+61.94%
Liquidity
Average Turnover Rate
60 days
+1.73%
120 days
+1.72%
5 years
--
Turnover Deviation
20 days
+1.68%
60 days
+13.73%
120 days
+13.34%
Peer Comparison
Pharmaceuticals
Evolus Inc
EOLS
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
9.11 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
RPRX
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kiniksa Pharmaceuticals International PLC
KNSA
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
8.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
